Halozyme Therapeutics, Inc. (HALO)
69.20
-2.10
(-2.94%)
USD |
NASDAQ |
Jan 23, 16:00
69.20
0.00 (0.00%)
After-Hours: 16:30
Halozyme Therapeutics Cash from Investing (Quarterly): 201.61M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Johnson & Johnson | -- |
| Merck & Co., Inc. | -283.00M |
| AIM ImmunoTech, Inc. | 0.296M |
| Stryker Corp. | -321.00M |
| Skye Bioscience, Inc. | 7.967M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 178.60M |
| Cash from Financing (Quarterly) | -22.40M |
| Free Cash Flow | 602.40M |
| Free Cash Flow Per Share (Quarterly) | 1.435 |
| Free Cash Flow to Equity (Quarterly) | 173.91M |
| Free Cash Flow to Firm (Quarterly) | 179.00M |
| Free Cash Flow Yield | 6.94% |